Shalby Limited (SHALBY) Fair Value & Analysis
Healthcare · IN · Market cap ₹18.6B
Fair value as of: Jul 3, 2026
From 16 valuation models · updated today
Share price −2.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹126.80 – ₹266.83 · fair‑value band ₹44.43 – ₹92.10 · the ₹172.22 price screens above the ₹63.00 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Shalby Limited (SHALBY) currently trades at ₹172.22, while our model-based Fair Value estimate is ₹63.00 — implying the stock looks roughly 63.4% overvalued today. We read business quality at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Shalby Limited generated revenue of ₹11.4B at a net margin of 3.3%. Revenue grew 8.5% year over year. It earns a return on equity of 3.5%. Net debt stands at ₹5.7B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Shalby Limited operates a chain of multi-specialty hospitals in India and internationally. The company operates through Healthcare Services and Manufacturing segments. It offers rheumatology, knee and hip joint replacement, spine surgery, orthopedic and trauma, arthroscopy, and arthroplasty; cardiothoracic and vascular surgery, coronary angiography, angioplasty and stenting, and cardiology services; root canal treatment, dental implants, crowns bridges, dentures, orthodontic treatment, dental cosmetic, teeth whitening, pediatric dentistry, dental veneers, gum treatment, and laser dentistry; dermatology; emergency and general medicine; cochlear implants and balloon sinuplasty; gastroenterology, obesity surgery, and endoscopy and laparoscopy; intensive and critical care; nephrology, urology, kidney transplant, dialysis, and interventional nephrology; and general surgery comprising varicose, hernia, and piles surgery. The company also provides liver transplant; maxillofacial surgery; …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Shalby Limited reported revenue of ₹11.4B in FY2026 versus ₹7.0B in FY2022, a compound +13.0%/yr. Reported net income was ₹374M in FY2026, compounding −8.8%/yr from FY2022.
Is SHALBY fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.30 | $8.61 | -24% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.67 MYR | 3.08 MYR | -64% |
| IHHHF IHHHF | $1.71 | $0.7400 | -57% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.76 | R$30.33 | -7% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shalby Limited (SHALBY) undervalued?
What is the fair value of SHALBY?
What is the quality score of SHALBY?
What is the revenue of Shalby Limited (SHALBY)?
What is the net profit margin of SHALBY?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.